Copyright
©The Author(s) 2015.
World J Gastroenterol. Dec 14, 2015; 21(46): 13087-13094
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13087
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13087
Table 1 Baseline characteristics
Characteristic | LAM group | History control group | ||||
No. | CHB | LC | No. | CHB | LC | |
(n = 238) | (n = 187) | (n = 51) | (n = 238) | (n = 190) | (n = 48) | |
Age (mean ± SD) | 35.9 ± 11.7 | 33.3 ± 10.3 | 45.5 ± 11.6 | 34.7 ± 11.5 | 32.3 ± 9.9 | 44.4 ± 12.0 |
Sex, n (%) | 197 (74.3) | 149 (70.6) | 48 (88.9) | 197 (74.3) | 153 (72.2) | 44 (83) |
Base HBeAg-positive, n (%) | 153 (57.7) | 134 (63.5) | 19 (35.2) | 157 (59.2) | 139 (65.6) | 18 (34) |
Base ALT (U/mL) | 150 | 157 | 124 | 212 | 221 | 173 |
Base HBV-DNA (copy/mL) | 5.85E+7 | 7.3E+7 | 5.4E+6 | 3.6E+7 | 2.1E+7 | 8.4E+7 |
Follow-up time (yr) | 5.1 (1.0-13.2) | 5.0 (1.0-13.2) | 5.2 (1.1-11.6) | 3.8 (1.0-17.6) | 3.9 (1.0-17.6) | 3.1 (1.0-15.0) |
- Citation: Su MH, Lu AL, Li SH, Zhong SH, Wang BJ, Wu XL, Mo YY, Liang P, Liu ZH, Xie R, He LX, Fu WD, Jiang JN. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. World J Gastroenterol 2015; 21(46): 13087-13094
- URL: https://www.wjgnet.com/1007-9327/full/v21/i46/13087.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i46.13087